Health Condition 1: M057- Rheumatoid arthritis with rheumatoid factor without organ or systems involvement
Conditions
Interventions
Intervention1: Itrifal Muqil Mulayyan & Roghan e Babuna Qawi: 1- Itrifal 5 gm twice daily after meal.
2- Ointment apply locally on affected area twice a day
Control Intervention1: Habb-e-Suranjan & Ro
Sponsors
Central Council for Research in Unani Medicine CCRUM New Delhi
Eligibility
Inclusion criteria
Inclusion criteria: Patients fulfilling the 2010 ACR-EULAR Rheumatoid Arthritis Classification Criteria
Exclusion criteria
Exclusion criteria: 1.Severe cases of RA (Stage III & IV) & diagnosed cases of ankylosing spondylosis/ Gout. 2.Cases with systemic manifestation of Rheumatoid arthritis. 3. Abnormality in any investigation done at baseline (SGOT, SGPT and ALP, Sr Creatinine, B. Urea would be considered abnormal if raised more than 2.5 times the normal value), also Patients with GFR less than 60 will be exclude from the study. 4. Patient with High grade fever. 5. Disorders requiring long term treatment. 6. Patient is on treatment for any illness related to Endocrine & metabolic disorders. 7. Pregnancy and lactation. 8. Drug addicts (Alcohol, drugs)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The safety and efficacy of Unani Pharmacopeial formulation Itrifal-e-Muqil Mullaiyan & Roghan e Babuna Qawi in comparison with Habb-e-Suranjan & Roghan e Suranjan in Waja ul Mafasil (Rheumatoid Arthritis) will be carried out on the basis of DAS28 FormTimepoint: At baseline and every two weeks during the treatment period. (i.e., 0, 2nd, 4th, 6th.8th, 10th and 12th weeks). | — |
Secondary
| Measure | Time frame |
|---|---|
| Haematological and biochemical investigations for safety assessment i.e., Hemogram, LFT,KFT, Urine Examination: Routine & Microscopic.Timepoint: At baseline and at the end of treatment. i.e., 0 and 12th week | — |
Countries
India
Contacts
Public ContactDr Pradeep Kumar
Central Council for Research in Unani Medicine (CCRUM)
Outcome results
None listed